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Abstract
BODY SIZE MISMATCH BETWEEN DONOR AND RECIPIENT IN CADAVERIC
KIDNEY TRANSPLANTATION.
LS Lee, LA Auersvald, EB Claus, MJ Bia, AL Friedman, MI Lorber, GP Basadonna.
Department of Surgery, Division of Organ Transplantation and Immunology and
Department of Internal Medicine, Division of Nephrology (MJB), Yale University School
of Medicine, New Haven, CT.

Recently much attention has focused on antigen independent mechanisms as
major contributors to late renal allograft loss. Nephron under-dosing at the time of
transplantation has been proposed to cause hyperfiltration and ultimately renal graft
failure1. Kidney size and nephron number have been successfully correlated with body
surface area (BSA)2'3. Using BSA as a proxy for nephron number, we investigated the
relationship between matching donor and recipient BSA and cadaveric renal allograft
survival. We studied the United Network of Organ Sharing renal transplant population in
this retrospective study using logistic and Cox regression analyses as well as actuarial
survival curves. These analyses revealed that a higher probability of graft failure was
associated with younger non-white recipients, older non-white donors, increased creatinine
at discharge, treatment for rejection before discharge, and a smaller BSA ratio of donor to
recipient. Our results demonstrate that while body size matching does affect long-term graft
survival, its effect is weaker than the more important determinants of long-term graft
survival, like creatinine at discharge, episodes of acute rejection before discharge,
recipient race, and recipient and donor age. Therefore, it does not appear that size matching
will significantly decrease the incidence of long-term allograft loss in cadaveric renal
transplantation.
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Introduction
With the advent of immunosuppressive drugs and improved post-transplant care,
short-term patient and graft survival following renal transplantation has steadily
improved over the past decade. One year graft survival rates range from 75% to over
80%'. However, the rate of late graft loss after the first post-transplant year has remained
unchanged1. Chronic rejection is the leading cause of late graft loss and accounts for
24%-67% of this graft loss4-6. Other significant causes include patient death with a
functioning transplant and noncompliance4'6.
Clinically chronic rejection is characterized by a gradual decline in glomerular
filtration rate, and is associated with proteinuria and hypertension after the first three or
six months post-transplantation

. Unlike with acute rejection, chronic rejection does not

respond to increased amounts of immunosuppressives. Histologically chronic rejection
may resemble acute rejection or grafts with no apparent dysfunction with mild to
moderate tissue infiltration by T cells and macrophages. In addition, chronic rejection is
characterized by vascular, glomerular, and tubulointerstitial lesions7.
Both immunologic and nonimmunologic factors have been implicated in late renal
allograft loss. Evidence supporting immune mediated mechanisms of late graft loss
include the greater frequency of chronic rejection in recipients of cadaveric rather than
living-related transplants9, the association of acute rejection with the development of
chronic rejection10’11, and the possible connection between chronic rejection and
inadequate immunosuppression secondary to noncompliance or concerns of the
nephrotoxic side effects of cyclosporine-A11. Several hypotheses have been proposed to
explain the immunologic basis for chronic rejection. CD4+ T helper cells coordinate the
immune response among the antigen presenting cells, macrophages, cytotoxic T cells,
and B cells through the release of cytokines. It is well known that two types of CD4+ T
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helper cells exist: TH1 clones which produce IFN-y and TNF-(3 leading to macrophage
and cytotoxic T cell activity and TH2 clones whose cytokines promote antibody
production1-. One hypothesis proposes that chronic rejection is the result of numerous
acute rejection episodes mediated by TH1 activated macrophages and cytotoxic T cells.
Another hypothesis argues that immunosuppression of TFi 1 cells leads to the dominance
of TH2 cells, which predominantly cause antibody-mediated graft damage leading to
chronic rejection. Whether chronic rejection results from a cellular or humoral mediated
mechanism, the target vascular antigen appears to be endothelial cells. Early vascular
rejection is correlated with late graft loss; i.e., the five year graft survival rate in this
group is 34% compared to 70% to 75% survival in patients never experiencing acute
rejection or having only interstitial rejection on biopsy7.
Recently much attention has focused on potential nonimmunologic factors
contributing to late graft loss. These include glomerular hyperfiltration, nephron dosing,
renal ischemic injury, systemic hypertension, hyperlipidemia, and drug toxicity. In many
animal models of renal injury, the adaptive changes of glomerular hyperfiltration and
hypertension have been shown to contribute to the progression of renal damage13.
Glomerular hyperfiltration and hypertension may lead to glomerulosclerosis and loss of
renal function.
Nephron dosing refers to the concept that when the metabolic demands exceed the
limit imposed by the nephron number, renal fibrosis is more likely to occur13. Loss of
renal mass leads to adaptive changes, including an increase in size and function of the
remaining nephrons. Animal models have demonstrated that a decrease in renal mass
may lead to proteinuria and glomerulosclerosis14-17. Clinical evidence exists to support
the nephron dosing hypothesis. Long-term graft survival of kidneys from donors that are
older (>50 years old), younger (<6 years old), or female and obese recipients is
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decreased18’19. Conflicting evidence exists regarding the impact of donor-recipient body
size mismatch on long-term graft survival20'23.
Delayed graft function due to renal ischemic injury occurs in 25% to 50% of
cadaveric transplant recipients13. Long-term graft survival is decreased in recipients with
delayed graft function24. Both immunologic as well as nonimmunologic mechanisms
may explain the contribution of delayed graft function to late graft loss. Studies have
shown that ischemia leads to the upregulation of class-II antigen expression on renal
endothelial cells, making the kidney more antigenic25. In addition, loss of renal mass
from ischemic injury leads to hyperfiltration and renal dysfunction.
Systemic hypertension has been negatively correlated with graft survival26. In
patients with chronic rejection, the degree of hypertension has been shown to correlate
with the severity of histologic change and the rate of decline of renal function. Few
studies have addressed the efficacy of the various antihypertensives in reducing the rate
of late graft loss. However, calcium-channel blockers are the agents of choice post¬
transplant because they also reduce cyclosporine-induced nephrotoxicity. Angiotensin¬
converting-enzyme inhibitors are used with caution because the combination with
cyclosporine has been shown to lead to acute renal failure15.
Pretransplant hyperlipidemia is a risk factor for late graft loss7. Oxidatively
modified LDL enhances a patient’s immune response13, and LDL is directly toxic to
endothelial cells7. Although renal damage itself may lead to the lipid abnormalities,
studies showing the presence of apolipoproteins in the vessel wall of grafts with chronic
rejection

and

vascular

intimal

hyperplasia

in

patients

with

pretransplant

hypercholesterolemia suggest that hyperlipidemia leads to graft atherosclerosis7’13.
Cyclosporine induces interstitial fibrosis by both causing ischemic damage from
chronic vasoconstriction and directly activating interstitial matrix formation13. Lower
doses of cyclosporine have been shown to cause an initial but not progressive decline in
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glomerular filtration rate13. However, too low doses of cyclosporine can lead to increased
rates of acute and chronic rejection11.
In this study we investigated the impact of the nonimmunologic factor of nephron
dosing on late renal allograft loss. We characterized a nationwide cadaveric renal
transplant patient population with respect to body size matching and examined the
relationship between donor/ recipient BSA ratio and renal allograft loss.
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Statement of Purpose
We intend to answer the question, ‘does body size matching affect long-term renal
allograft survival?’ using a retrospective study to investigate 25,092 patients from the
United Network of Organ Sharing (UNOS) Scientific Renal Transplant Registry.
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Methods
Data regarding 25,092 patients who underwent cadaveric renal transplantation
between October 1, 1987 and December 31, 1993 were obtained from the UNOS
Scientific Renal Transplant Registry. Among them, 3039 patients experienced graft loss
and the 22,053 patients who maintained good graft function at last follow-up were used
as controls. Descriptive statistics were performed by donor/ recipient status for cases and
controls using means and percentages. Differences in demographic and clinical variables
between cases and controls by donor/ recipient status were assessed using t-tests and chisquare tests for continuous and binary variables, respectively. The independent variable
of interest, body surface area ratio (BSR), was defined as BSA donor/ BSA recipient
where BSA was calculated according to the following formula (Costeff’s rule): BSA (m2)
= (4*weight (kg) +

1)1

(90+weight)27. Additional independent variables included age,

gender, and race of recipient and donor as well as creatinine of recipient at discharge,
number of transplants, and treatment for rejection before discharge.
The outcome variable, renal graft loss, was analyzed both as a binary variable
(graft loss/ no graft loss) and as a continuous variable (time to graft loss). Logistic
regression was used to measure the effect of BSR on the probability of graft loss while a
Cox proportional hazards model was used to measure the impact of BSR on the time to
graft loss. The logistic and Cox regression models provided unadjusted odds ratios and
relative risks, respectively, with 95% confidence. Significant variables associated with
allograft loss on univariate analysis were incorporated into a multivariate model to obtain
adjusted odds ratios and relative risks. Multivariate analyses were conducted using the
stepwise selection procedure with entry and exit criteria set at p=Q.05.
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Initially the effect of BSR on graft loss and time to graft loss was examined with
BSR as a continuous variable. To obtain a more clinically meaningful odds ratio, BSR
was also redefined by pairs of binary dummy variables. These variables allowed
comparison of graft loss rates among four categories of BSR: 0-0.80, 0.81-1.50, 1.511.80, and >1.80 with 0-0.80 as the baseline category. These cut points were selected
based upon the distribution of graft loss rates by BSR grouping (Figure 1).
Kaplan-Meier curves and log-rank tests were used to compare the renal graft
survival curves of patients in the four different BSR groups. Renal graft survival was also
analyzed by subgrouping the recipients by gender and race.
Data are expressed as means ± SE. All analyses were performed using PC-SAS
version 6.05.
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Figure 1. Proportion of Graft Loss in BSA ratio
Intervals
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Results
Recipient characteristics are shown in Table 1. Control and case recipients were
well matched for gender only while the donors for the controls and cases were
significantly different regarding each of the demographic variables. Mean BSA ratio for
all recipients was 1.00 ±0.002. The mean difference in BSA between the paired donor
and recipient of the controls was 0.036 ± 0.003. This was significantly different from that
between the paired donor and recipient of the cases (0.098 ± 0.008). Therefore, the
controls were better size-matched than the cases. Median number of days of follow-up
was 687 days by which time 78.6% (2389) of the 3039 graft losses had occurred. By the
first 400 days post-transplantation, 47% of the graft losses had occurred. At five years the
number of recipients without graft failure and remaining in follow-up was 105.
Univariate analyses of the variables revealed that recipient age and race, donor
age, gender, and race, creatinine at discharge, number of transplants, treatment for
rejection before discharge, and BSA ratio all had a significant effect on graft loss (Tables
2, 3). Recipients with a BSA ratio <0.8 had a 1.479 greater risk of graft loss compared to
those with a BSA ratio >0.8. Similar results were obtained with the multivariate logistic
and Cox analyses (Tables 2, 3). A higher probability of renal graft loss was associated
with the younger, non-white recipient treated for rejection before discharge with a high
discharge creatinine and a BSA ratio <0.8 who receives a renal graft for the second or
third time from an older, non-white, female donor. The most important determinants of
graft failure were creatinine at discharge, treatment for rejection before discharge, and
recipient age and race. Although a relatively weak risk factor for graft loss, BSA ratio
was more important than donor age and race (donor race and transplant number in the
Cox regression model). Only donor gender (and number of transplants in the logistic
model) was not a significant risk factor for graft loss in the multivariate analyses.
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Table 1 Donor and Recipient Characteristics

Case

Control
recipient

donor

recipient

donor

mean age

42.2 ±0.09*

30.7 ±0.1 1*

39.2 ±0.25*

32.6 ±0.32*

male / female

61 / 39

64/36*

60 / 40

60 / 40*

white / non-white

75 /25*

89/11*

63 / 37*

86/ 14*

mean creatinine at discharge

2.27 ±0.01*

3.31 ±0.05*

treated for rejection before
discharge (N/Y)

3.0*

1.8*

1° / retransplant

19.0*

15.7*

mean D/R BSA ratio

1.01 ±0.002*

0.98±0.007*

* p value <0.05

Table 2. Logistic Regression: Graft Loss (n=25,092)

Univariate

Multivariate

Independent variable

p value*

Odds ratio (95%
p value**
Confidence Interval)

Odds ratio (95%
Confidence Interval)

creatinine at discharge

0.0001

1.180(1.163, 1.198)

0.0001

1.148 (1.130, 1.165)

treated for rejection
before discharge (Y/N)

0.0001

1.688 (1.558, 1.828)

0.0001

1.571 (1.448, 1.705)

recipient race
(non-white vs. white)

0.0001

1.722 (1.590, 1.864)

0.0001

1.519 (1.397, 1.651)

recipient age

0.0001

0.984 (0.981,0.987)

0.0001

0.983 (0.980, 0.986)

D/R BSA ratio

0.0001

1.451 (1.258, 1.675)

0.0001

1.541 (1.342, 1.715)

D/R BSA ratio group
(<0.8 vs. >0.8)

0.0001

1.479 (1.344, 1.631)

0.0001

1.567 (1.404, 1.751)

donor age

0.0001

1.007 (1.005, 1.010)

0.0001

1.009 (1.006, 1.012)

donor race
(non-white vs. white)

0.0001

1.365 (1.223, 1.523)

0.0002

1.237 (1.102, 1.388)

number of transplants
(retransplant vs. 1 °)

0.0027

1.262 (1.084, 1.469)

-

-

donor gender
(female vs. male)

0.0001

1.208 (1.118, 1.306)

0.0481

1.088 (1.001, 1.182)

* p value< 0.05
** p value< 0.006
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Table 3. Cox Regression: Graft Loss (n= 25,092)

Multivariate

Univariate
Indepencient variable

p value*

Risk ratio (95%
p value**
Confidence Interval)

Risk ratio (95%
Confidence Interval)

creatinine at discharge

0.0001

1.070 (1.065, 1.075)

0.0001

1.062 (1.056, 1.068)

recipient race
(non-white vs. white)

0.0001

1.657 (1.540, 1.783)

0.0001

1.519 (1.416, 1.646)

treated for rejection
before discharge (Y/N)

0.0001

1.581 (1.468, 1.703)

0.0001

1.535 (1.425, 1.653)

recipient age

0.0001

0.987 (0.985,0.990)

0.0001

0.987 (0.984, 0.989)

donor age

0.0001

1.009 (1.007, 1.01 1)

0.0001

1.012 (1.010, 1.015)

D/R BSA ratio

0.0001

1.468 (1.281, 1.683)

0.0001

1.676 (1.534, 1.841)

D/R BSA ratio group
(<0.8 vs. >0.8)

0.0001

1.449 (1.325, 1.584)

0.0001

1.585 (1.436, 1.750)

donor race
(non-white vs. white)

0.0001

1.396(1.262, 1.545)

0.0001

1.313 (1.183, 1.457)

number of transplants
(retransplant vs. 1°)

0.0001

1.321 (1.148, 1.520)

0.0010

1.270(1.102, 1.463)

donor gender
(female vs. male)

0.0001

1.215 (1.130, 1.306)

0.0393

1.084 (1.004, 1.171)

* p value< 0.05
** p value< 0.006
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Recipients in the BSA ratio group >0.8 had a significantly higher 5 year actuarial
graft survival rate than recipients with a BSA ratio <0.8 (controls: 78%, cases: 74%)
(Figure 2). The difference in survival rate between the two patient groups remained
around 4% throughout the entire 5 year period studied. Similar results were obtained
when 5 year actuarial graft survival rates were compared for patients with extreme BSA
ratios (group 1: <0.5, group 2: 0.95-1.05, group 3: >1.5). The 5 year graft survival rate of
group 1 was 4% lower than the other 2 groups (p<0.05). Analyses of recipients first
subdivided according to race or gender and then by BSA ratio group revealed the same
results. There was also a significant effect on graft survival by race alone.
The recipients were reanalyzed after removing those patients who had lost their
renal grafts within the first year post-transplantation. Recipients who lost their grafts
were younger with more non-whites, a higher mean creatinine at discharge, and more
treatment for rejection before discharge than the control recipients (p<0.05). The gender
distribution and mean BSA ratio for the two recipient groups were not significantly
different. The donors for the recipients who lost the grafts were older with more non¬
whites (p<0.05). Multivariate analyses revealed similar results as with all the patients
(Tables 4, 5). However, the Kaplan-Meier actuarial graft survival curves did not show a
significant difference in survival rates between recipients with a small (<0.8) versus a
large (>0.8) BSA ratio.
There were 1814 transplantations from pediatric donors <10 years of age. Of
these, 1616 recipients had a BSA ratio <0.8 while the other 198 had a BSA ratio >0.8.
There was no difference in the 5 year graft survival rates for the two BSA ratio groups.
However, these recipients of pediatric kidneys had a 2% lower graft survival rate at five
years than recipients with adult donors (p<0.05).
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Figure 2. Survival of Kidney Grafts according to BSA ratio
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Table 4. Logistic Regression: Graft Loss >lyear post-transplantation (n=23237)

Multivariate
Independent variable

p value*

Odds ratio (95%
Confidence Interval)

recipient race (non-white vs. white)

0.0001

2.349 (2.085, 2.647)

recipient age

0.0001

0.973 (0.969, 0.978)

donor age

0.0001

1.009 (1.005, 1.013)

treated for rejection before discharge (Y/N)

0.0001

1.296 (1.140, 1.473)

D/R BSA ratio group (<0.8 vs. >0.8)

0.0019

1.311 (1.105, 1.556)

creatinine at discharge

0.0052

1.030 (1.009, 1.051)

* p<Q.Q06
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Table 5. Cox regression: Graft Loss >1 year post-transplantation (n=23237)

Multivariate
Independent variable

p value*

Risk ratio (95%
Confidence Interval)

recipient race (non-white vs. white)

0.0001

2.341 (2.084, 2.630)

recipient age

0.0001

0.977 (0.973, 0.981)

donor age

0.0001

1.015 (1.01 1, 1.019)

creatinine at discharge

0.0001

1.039 (0.883, 1.057)

D/R BSA ratio group (<0.8 vs. >0.8)

0.0001

1.374 (1.167, 1.617)

treated for rejection before discharge (Y/N)

0.0073

1.183 (1.046, 1.338)

donor race (non-white vs. white)

0.0231

1.217 (1.027, 1.442)

number of transplants (retransplant vs. 1 )

0.0370

1.285 (1.015, 1.625)

* p value< 0.006
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Discussion

Long-term renal allograft survival remains unchanged despite tremendous
advances in immunosuppression and post-transplant care. Recently much attention has
been focused on antigen independent mechanisms as major contributors to late renal
allograft loss. Rat models, including Shimamura and Morrison's five-sixths nephrectomy
model14, Hostetter and colleagues’ eleven-twelths model28, and Brenner and associates’
five-sixths model15, have all demonstrated the deleterious effect of nephron dosing on
long-term renal graft survival. Reductions in nephron mass to one-sixth accelerated the
development of proteinuria and glomerulosclerosis regardless of the immunogenicity of
the transplanted organ15. Leaving a native kidney in the transplanted rats protected them
from these changes16. Furthermore, expression of cell surface molecules, cytokine
production, and infiltration of macrophages in renal tissue was modulated by nephron
mass17.
Several natural and man-made experiments in human beings exist that assess the
nephron dosing hypothesis. These models include unilateral renal agenesis, unilateral
nephrectomy for renal disease, and donor nephrectomy. Unilateral renal agenesis is
associated with

an

increased incidence of proteinuria and

focal

segmental

glomerulosclerosis. Long-term follow-up of patients with unilateral nephrectomy
secondary to renal disease or donor status failed to demonstrate these adverse outcomes.
However, proteinuria and focal segmental glomerulosclerosis occurred in patients with a
single kidney who further underwent between 25% and 75% nephrectomy of this solitary
kidney for renal carcinoma29.
Clinical evidence exists to suggest a link between nephron dosing and long-term
graft outcome. Diminished graft survival is associated with donors who are aged 4 to 6,
older (>50), female, black, or cadaveric, obese recipients (> 100kg), and kidneys that

18

experienced rejection episodes18’19’30. The ideal experiment to demonstrate the impact of
nephron dosing on long-term graft survival in human beings would replicate the animal
studies by comparing single versus double kidney transplants. However, this is hardly
feasible given the grave disparity between the supply and demand for kidneys. No
prospective data exist. Therefore, we were limited to a retrospective study of single
kidney recipients.
Several retrospective studies have examined the impact of donor/ recipient size
matching on long-term graft survival. Kupin and colleagues found lower donor/ recipient
BSA ratios (0.8810.1) in recipients with transplant glomerulopathy than in those with
normal graft function (1.010.2). However, the former recipients had other reasons to
develop graft failure, including 84% being African American who were poorly HLA
matched with multiple episodes of acute rejection-0. The ratio of donor kidney weight to
recipient body weight did not impact graft survival in over 300 patients studied by Roth
and co-workers-1. Miles and associates studied over 150 patients using the ratio of renal
volume to recipient BSA and found no effect on graft survival22. Similarly, the variable
of interest, the ratio of donor/ recipient BSA, for Gaston and colleagues did not affect
graft survival and renal function as measured by serum creatinine levels23.
Our study is the largest to date and may explain the different results obtained from
Roth et al., Miles et al., and Gaston et al. The studies to date examining the effect of
donor/ recipient size matching suggest that whatever impact nephron dosing has on long¬
term renal allograft survival is overshadowed by other clinical parameters. Our study
confirms these findings. We have demonstrated that the donor/ recipient BSA ratio of
cadaveric renal transplants in the United States does have a statistically significant impact
on long-term allograft loss. However, its effect is weak compared to the most important
determinants of long-term graft survival like creatinine at discharge, episodes of acute
rejection, and recipient race. These results were duplicated when we analyzed only the
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patients with a graft surviving for at least one year post-transplantation. In comparing the
four categories of BSA ratio, recipients with a BSA at least 20% larger than their donors
fared worse than the recipients with a smaller BSA in both the multivariate regression
and survival analyses. The former recipients experienced a 4% lower survival rate which
remained constant throughout the 5 year follow-up. This absolute value, while
statistically significant, was not impressive. In the nephron dosing hypothesis, one may
expect the survival curves to diverge over the years as the allograft loses more nephrons.
This was not seen in our analyses using the four original as well as the three extreme
BSA ratio categories.
In examining the patient population, the majority of recipients were already well
size matched. Although the difference in mean BSA ratios between the controls and cases
was statistically significant, the absolute values revealed a negligible difference (controls:
1.01, cases: 0.98). Similarly, while the mean difference in BSA between the pairs of
donors and recipients for the controls versus the cases was significantly different, the
actual numbers were not impressive (controls: 0.036, cases: 0.098). However, the trend of
these values with the recipients experiencing graft loss being slightly larger than their
donors and more poorly size matched with their donors than the control recipients
supports the idea that recipients with a smaller nephron dose are more likely to develop
late graft failure.
In this retrospective study using donor/ recipient BSA ratio as a surrogate for
nephron dosing, we demonstrate that while body size matching does affect cadaveric
renal allograft survival up to 5 years post-transplantation, its effect is overshadowed by
other clinical factors. Therefore, it does not appear that prospective size matching will
significantly decrease the incidence of late allograft loss in cadaveric renal transplant
recipients.
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